Been waiting for this week for a loooonnnggg time.
Post# of 30028
The addition of Donald is fantastic. One more jewel in the crown.
I am going to assume that LymPro data is good/excellent for the sake of this post.
My best guess is .25 by Friday.
Revenue guidance = another .05 - .10 cents.
LymPro partnership adds .10 -.20 cents dependent on up front payments. If it is both a CLIA partner and Pharma partner for FDA approval, could be more.
This would put pps at .40 - .55 cents by end of August.
You throw in some additional MANF catalysts/partnerships and we're looking at .75 - 1.00 by up listing.
I'm finally allowing my imagination to run free.
Great times ahead.